-Feb 26, 20228 min read TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISONReminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...
-Feb 20, 202216 min readINKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGYSummary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...
-Jan 23, 202213 min readTHE TEN BILLION UNICORN IN INMB: ON MY INVESTMENT THESIS AND INMB’s PRICE MOVEMENTS In my mind's eye, these stairs keep on going into 2023 and the years after. INTRODUCTION The previous five blogs have laid out the...
-Dec 29, 202110 min readTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNEThe immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.
-Dec 21, 202114 min readTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNEINTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....